Last reviewed · How we verify
insulin-like growth factor I
Insulin-like growth factor I (IGF-I) binds to the IGF-1 receptor to promote cell growth, proliferation, and metabolic effects.
Insulin-like growth factor I (IGF-I) binds to the IGF-1 receptor to promote cell growth, proliferation, and metabolic effects. Used for Growth failure due to IGF-I deficiency (primary IGFD), Short stature associated with severe insulin-like growth factor-I deficiency.
At a glance
| Generic name | insulin-like growth factor I |
|---|---|
| Sponsor | Children's Hospital of Philadelphia |
| Drug class | Growth factor; recombinant peptide hormone |
| Target | IGF-1 receptor (IGF1R) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Growth disorders |
| Phase | FDA-approved |
Mechanism of action
IGF-I is a naturally occurring peptide hormone that activates the IGF-1 receptor tyrosine kinase, triggering intracellular signaling cascades that stimulate protein synthesis, cell division, and glucose uptake. It plays a critical role in growth and development, particularly in childhood, and has been used therapeutically to treat growth disorders and metabolic conditions associated with IGF-I deficiency.
Approved indications
- Growth failure due to IGF-I deficiency (primary IGFD)
- Short stature associated with severe insulin-like growth factor-I deficiency
Common side effects
- Hypoglycemia
- Injection site reactions
- Headache
- Ear abnormalities (otitis media)
- Lymphoid tissue hypertrophy
Key clinical trials
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- System-IGF-1 Pathway and Alzheimer's Disease
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (PHASE3)
- Impact of Filtration on Autologous Serum Eye Drops (NA)
- Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin-like growth factor I CI brief — competitive landscape report
- insulin-like growth factor I updates RSS · CI watch RSS
- Children's Hospital of Philadelphia portfolio CI